Literature DB >> 22658217

Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.

Brian C Baumann1, Thomas J Guzzo, Jiwei He, David J Vaughn, Stephen M Keefe, Neha Vapiwala, Curtiland Deville, Justin E Bekelman, Kai Tucker, Wei-Ting Hwang, S Bruce Malkowicz, John P Christodouleas.   

Abstract

PURPOSE: Local-regional failures (LFs) after cystectomy with or without chemotherapy are common in locally advanced disease. Adjuvant radiation therapy (RT) could reduce LFs, but toxicity has discouraged its use. Modern RT techniques with improved normal tissue sparing have rekindled interest but require knowledge of pelvic failure patterns to design treatment volumes. METHODS AND MATERIALS: Five-year LF rates after radical cystectomy plus pelvic node dissection with or without chemotherapy were determined for 8 pelvic sites among 442 urothelial bladder carcinoma patients. The impact of pathologic stage, margin status, nodal involvement, and extent of node dissection on failure patterns was assessed using competing risk analysis. We calculated the percentage of patients whose sites of LF would have been completely encompassed within various hypothetical clinical target volumes (CTVs) for postoperative radiation.
RESULTS: Compared with stage ≤pT2, stage ≥pT3 patients had higher 5-year LF rates in virtually all pelvic sites. Among stage ≥pT3 patients, margin status significantly altered the failure pattern whereas extent of node dissection and nodal positivity did not. In stage ≥pT3 patients with negative margins, failure occurred predominantly in the iliac/obturator nodes and uncommonly in the cystectomy bed and/or presacral nodes. Of these patients in whom failure subsequently occurred, 76% would have had all LF sites encompassed within CTVs covering only the iliac/obturator nodes. In stage ≥pT3 with positive margins, cystectomy bed and/or presacral nodal failures increased significantly. Only 57% of such patients had all LF sites within CTVs limited to the iliac/obturator nodes, but including the cystectomy bed and presacral nodes in the CTV when margins were positive increased the percentage of LFs encompassed to 91%.
CONCLUSIONS: Patterns of failure within the pelvis are summarized to facilitate design of adjuvant RT protocols. These data suggest that RT should target at least the iliac/obturator nodes in stage ≥pT3 with negative margins; coverage of the presacral nodes and cystectomy bed may be necessary for stage ≥pT3 with positive margins.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22658217     DOI: 10.1016/j.ijrobp.2012.03.061

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  [Prediction of local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. A novel risk stratification].

Authors:  C Weiss
Journal:  Strahlenther Onkol       Date:  2013-11       Impact factor: 3.621

2.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.

Authors:  Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann
Journal:  JAMA Surg       Date:  2018-01-17       Impact factor: 14.766

3.  Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer.

Authors:  Chelsea K Osterman; Jaber Alanzi; James D Lewis; Elizabeth L Kaufman; Vivek Narayan; Ben Boursi; Ravy K Vajravelu; Frank I Scott; S Bruce Malkowicz; Ronac Mamtani
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

4.  National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013.

Authors:  Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand
Journal:  Eur Urol Oncol       Date:  2018-12-19

5.  Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.

Authors:  Brian C Baumann; Walter R Bosch; Amit Bahl; Alison J Birtle; Rodney H Breau; Amarnath Challapalli; Albert J Chang; Ananya Choudhury; Sia Daneshmand; Ali El-Gayed; Adam Feldman; Steven E Finkelstein; Thomas J Guzzo; Serena Hilman; Ashesh Jani; S Bruce Malkowicz; Constantine A Mantz; Viraj Master; Anita V Mitra; Vedang Murthy; Sima P Porten; Pierre M Richaud; Paul Sargos; Jason A Efstathiou; Libni J Eapen; John P Christodouleas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-07       Impact factor: 7.038

6.  The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer.

Authors:  Gary D Lewis; Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  Bladder Cancer       Date:  2018-04-26

Review 7.  Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?

Authors:  Paul Sargos; Brian C Baumann; Libni J Eapen; Amit Bahl; Vedang Murthy; Guilhem Roubaud; Mathieu Orré; Jason A Efstathiou; Shahrokh Shariat; Stephane Larré; Pierre Richaud; John P Christodouleas
Journal:  Transl Androl Urol       Date:  2016-10

Review 8.  The Rationale for Post-Operative Radiation in Localized Bladder Cancer.

Authors:  Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas
Journal:  Bladder Cancer       Date:  2017-01-27

9.  Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?

Authors:  Kevin Lm Chua; Grace Kusumawidjaja; Jure Murgic; Melvin Lk Chua
Journal:  ESMO Open       Date:  2017-03-07

10.  Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.

Authors:  Joshua B Kaelberer; Michael A O'Donnell; Darrion L Mitchell; Anthony N Snow; Sarah L Mott; John M Buatti; Mark C Smith; John M Watkins
Journal:  Prostate Int       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.